AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
Subscribe To Our Newsletter & Stay Updated